Celldex Therapeutics, Inc. — Director's Dealing 2023

Feb 21, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2023-02-16

Reporting Person: Jain Rita (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-16	Non-Qualified Stock Option (right to buy)	$42.34	A	17100	Acquired	2033-02-16	Common Stock (17100)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2: One third vests on the first, second and third anniversaries of the date of grant.